Beigene Ltd (ADR)  

(Public, NASDAQ:BGNE)   Watch this stock  
Find more results for BGNE
-0.15 (-0.18%)
Real-time:   3:59PM EDT
NASDAQ real-time data - Disclaimer
Currency in USD
Range 82.18 - 84.97
52 week 26.43 - 118.95
Open 84.20
Vol / Avg. 294,488.00/311,955.00
Mkt cap 3.56B
P/E     -
Div/yield     -
EPS -4.93
Shares 518.90M
Beta     -
Inst. own 4%
Nov 8, 2017
Q3 2017 BeiGene Ltd Earnings Release (Estimated) - 4:00PM EST - Add to calendar
Sep 12, 2017
BeiGene Ltd at Morgan Stanley Healthcare Conference - Webcast
Sep 6, 2017
BeiGene Ltd at Robert W Baird Gobal Healthcare Conference - Webcast
Aug 9, 2017
Q2 2017 BeiGene Ltd Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '17) 2016
Net profit margin - -11141.78%
Operating margin - -10940.19%
EBITD margin - -10761.78%
Return on average assets -57.22% -45.63%
Return on average equity -86.09% -94.94%
Employees 321 -
CDP Score - -


C/O Mourant Ozannes Corporate Services 94 Solaris Avenue, Camana Bay
Cayman Islands
+1-345-9494123 (Phone)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


BeiGene, Ltd. is a clinical-stage biopharmaceutical company. The Company is focused in the discovery and development of molecularly targeted and immuno-oncology drugs for the treatment of cancer. The Company had used its cancer biology platform to develop four clinical-stage drug candidates, such as BGB-3111, BGB-A317, BGB-290 and BGB-283, as of December 31, 2016. BGB-3111, BGB-290 and BGB-283 are its molecularly targeted agents and is its immuno-oncology agent. BGB-3111 is a potent and highly selective small molecule inhibitor of Bruton's tyrosine kinase (BTK). BGB-283 is a molecule inhibitor of both the monomer and dimer forms of the RAF kinase. BGB-290 is a molecularly targeted, orally available, potent and highly selective inhibitor of the poly ADP ribose polymerase (PARP) family members. BGB-A317 is an investigational humanized monoclonal antibody against the immune checkpoint receptor, PD-1.

Officers and directors

John V Oyler Chairman of the Board, Chief Executive Officer, Founder
Age: 48
Bio & Compensation  - Reuters
Howard Liang Ph.D. Chief Financial Officer and Chief Strategy Officer
Age: 52
Bio & Compensation  - Reuters
Wendy Yan Senior Vice President, Head of Regulatory Affairs
Age: 50
Bio & Compensation  - Reuters
Jason Yang M.D.Suffix is Ph.D. Senior Vice President, Head of Clinical Development
Age: 51
Bio & Compensation  - Reuters
Timothy Y. Chen Director
Age: 59
Bio & Compensation  - Reuters
Donald W. Glazer Director
Age: 71
Bio & Compensation  - Reuters
Michael J. Goller Director
Age: 40
Bio & Compensation  - Reuters
Ranjeev Krishana Director
Age: 41
Bio & Compensation  - Reuters
Xiaodong Wang Ph.D. Director
Age: 52
Bio & Compensation  - Reuters